key: cord-0623892-4ejcmts0
authors: Johnson, Kory D.; Grass, Annemarie; Toneian, Daniel; Beiglbock, Mathias; Polechov'a, Jitka
title: Robust models of SARS-CoV-2 heterogeneity and control
date: 2021-09-23
journal: nan
DOI: nan
sha: c0f31b9611dabf43222e77e04b86dc5b9c249328
doc_id: 623892
cord_uid: 4ejcmts0

In light of the continuing emergence of new SARS-CoV-2 variants and vaccines, we create a simulation framework for exploring possible infection trajectories under various scenarios. The situations of primary interest involve the interaction between three components: vaccination campaigns, non-pharmaceutical interventions (NPIs), and the emergence of new SARS-CoV-2 variants. Additionally, immunity waning and vaccine boosters are modeled to account for their growing importance. New infections are generated according to a hierarchical model in which people have a random, individual infectiousness. The model thus includes super-spreading observed in the COVID-19 pandemic. Our simulation functions as a dynamic compartment model in which an individual's history of infection, vaccination, and possible reinfection all play a role in their resistance to further infections. We present a risk measure for each SARS-CoV-2 variant, $rho^V$, that accounts for the amount of resistance within a population and show how this risk changes as the vaccination rate increases. Furthermore, by considering different population compositions in terms of previous infection and type of vaccination, we can learn about variants which pose differential risk to different countries. Different control strategies are implemented which aim to both suppress COVID-19 outbreaks when they occur as well as relax restrictions when possible. We demonstrate that a controller that responds to the effective reproduction number in addition to case numbers is more efficient and effective in controlling new waves than monitoring case numbers alone. This is of interest as the majority of the public discussion and well-known statistics deal primarily with case numbers.

following recursion:

where R e,t is the time-varying effective reproduction number at time t, w = (w 1 , . . . , w ν )

is the generation interval, and ν is the maximum number of days for which someone is assumed to be infectious. If J m denotes the number of people infected by a specific person on the m-th day after this person got infected, then we have for m ∈ N

.

We assume that a newly infected individual does not cause secondary infections on the same day, corresponding to w 0 = 0, and that infections do not occur after day ν.

The generation interval can be interpreted as the infectiousness profile of infected persons. We set w to be a discretized gamma distribution with ν = 13, mean 4.46, and standard deviation 2.63. These are values specific to Austria [9] , and are similar to values determined elsewhere [10] [11] [12] . We note that the framework is general enough to allow each variant to be specified with a unique generation interval. This is potentially useful for modeling future variants, as the recently prominent Omicron (B.1.1.529) variant appears to have a shorter generation time [13] .

The recursion in equation (1) assumes that all people have the same infectiousness on day t. We follow [7] and remove this assumption by explicitly drawing an infectiousness parameter for each infected person from a fixed Gamma distribution with dispersion parameter k < 1. This generalization allows for superspreading: the phenomenon of extreme heterogeneity in infectiousness. We set k = 0.1, which corresponds to a setting in which 10% of infected individuals cause 80% of new infections [14] . This is an integral component of the difficulty of controlling COVID-19

outbreaks. Individual infectiousness can be aggregated over the infected, resulting in the following process of new infections:

θ s ∼ Gamma(I s k, rate = k/R e,t ).

January 10, 2022 5/48

We generalize this model further in order to study the effect of combinations of variants, previous infections, vaccination strategies, and NPIs -and interactions between them -on the effective reproduction number R e,t . This is done by decomposing R e,t into many constituent parts which depend on the compartments in our model. In order to describe this decomposition, we need notation for compartments.

Our model contains a set of compartments C . Each compartment C ∈ C is a group The only characteristics of the history that affect the model are the total set of experiences (vaccines or infections) as well as the final infection, as this determines the variant one is infectious with. Furthermore, reinfection with the same variant does not confer additional benefit. Hence we can simplify histories to those that have no repeated capital letters. Lastly, it will often be easier to write equations using the set of histories, H , instead of the corresponding set of compartments, C . As h ∈ H is the identifier of a compartment, we will also at times call it a compartment for ease of use.

Each group C h contains the total number of people with that history, both infected (I h ) and recovered (S h ), which are subgroups with the same labels: C h = I h ∪ S h . The recovered (or vaccinated) subgroup is written as S h to emphasize that they are again susceptible to infection, though with a resistance parameter depending on h as described below. All are given subscripts t, though for consistency with the generating equations, the subscripted groups have different interpretations. C h t and S h t contain all people on day t with history h and the subset that are recovered, respectively. I h t gives the number of new infections with history h on day t. For simplicity, individuals recover January 10, 2022 6/48 ν + 1 days after being infected. We assume that when one is experiencing an infection, they cannot become newly infected (or receive a vaccine). With these simplifications, we have |C h t | = |S h t | + ν m=1 I h t−m . Note that notation for I h t has been overloaded to either be the set of people with new infections with history h or the cardinality of this set.

This provides consistency with the generating equation (2) .

An important aspect of the simulation is that interaction groups are created dynamically. For example, someone in S h t can be infected with a SARS-CoV-2 variant There is a specific R hV e,t for all compartments h ∈ H and all infectious variants V ∈ V , where group S h t is susceptible to infection with V on day t. This can be interpreted as the effective reproduction number of variant V solely within group C h . As data are often reported in terms of relative transmissibility of SARS-CoV-2 variants, each variant V has a basic reproduction number relative to that of the original SARS-CoV-2 variant given by

With this group-specific notation, we can define a decomposition of R hV e,t as

where Table 1 in the Appendix.

believed that SARS-CoV-2 follows a seasonal transmission pattern in temperate regions with transmissions peaking during the winter. Possible explanations include different viral longevity due to humidity and air temperature [17, 18] , reduced host airway immune response in dry winter months [16, 19] , and increased indoor interactions during colder months. We model seasonality, L t , as in [20] via a cosine transform:

where is the amplitude size and t peak is the date when the transmission rate peaks.

Following [21] , we assume that the seasonal reduction in transmission is 40% ( = 0.4); the lowest transmission rate is set to July 1, while the highest transmission rate occurs on t peak = January 1. This is in line with the estimates for the general seasonality of other coronaviruses in temperate climates [15] . history g, the resistance to an infection with SARS-CoV-2 variant V is given by

Thus, the susceptibility to variant V declines as a product of the susceptibility to V conferred by the history h,γ hV , and the susceptibility to V conferred by the infection V,γ VV . Note that repeated infections with the same variant, i.e. V ∈ h, then resistances are not updated.

We note here that interactions between groups are only considered in terms of resistances, not in terms of infectiousness; a vaccinated individual that nevertheless gets infected with variant V is considered equally infectious as an unvaccinated individual infected with variant V. This is a simplification -in reality, the viral load in infected, vaccinated individuals appears to decline faster (and is hence lower on average) [22] . In addition, for the same nasopharyngeal viral load (C t s), the probability of detecting an infectious virus using cell culture is also slightly lower [23] . Each C h creates new infections in S g according to equations (2) and (3). We then sum over these groups:

and N is the total population size, N = C∈C |C|. 

We assume a controller is interested in constraining the process of new infections, Changes in non-pharmaceutical interventions (NPIs) are concretely implemented by settingM t+1 = δM t in equation (8) . Thus, increase in NPIs such as mask mandates have the effect of a multiplicative decrease in transmissibility. We have explicitly assumed a certain compound effect of NPIs rather than specifying them. Our goal is not to prescribe which combination of NPIs to use, but to demonstrate differences in efficiency of containment strategies that result from using different statistics to guide the decision on the timing of the NPIs.

We consider two types of controllers which react to different statistics computed from case data. Both increase and decrease mitigation,M , by some proportion δ ∈ [0, 1] whenever they intervene. The first controller changes the effect of NPIs when daily cases pass pre-specified boundaries and is termed a "reactive" controller. This is a controller which increases NPIs when reported daily cases are over some high threshold We have:

Here, we have ignored the small number of currently infected individuals by dividing by

Equation (10) provides a useful summary as an average effect implied by our model which accounts for variant heterogeneity, population diversity, and superspreading.

Unfortunately, a controller cannot compute it as it depends on the unknown parameters θ h , which describe the "momentum" of the disease [7] . A feasible estimator does not consider θ h t to be known, instead using the expected total current infectiousness of V given λ V and R 0 :

We note that the statistic above is not meant to be an ideal estimate of the effective reproduction number R e,t , but instead functions as a computationally efficient way to track the spread of infections in a way that is consistent with our simulation framework.

While quantities such as |S g t | are not known in practice, they can be estimated per variant and vaccine. In fact, this is done when initializing our model and is described extensively in Section Initializing the Simulation along with estimation of (12).

A "proactive" controller changes mitigation measures based onR e,t and case numbers. Behavior is the same as for the reactive controller, except that there is also an upper bound specified forR e,t : when the effective reproduction number is higher than this upper bound, restrictions are increased. Reducing restrictions requiresR e,t < 1 in addition to low case numbers. In general, their relative advantage and effective reproduction number depend on the composition of the population. The first row of Table 1 shows the assumed relative advantage of variant V over the wild-type,

, in a naïve population. The values are computed from recent estimates of R V e /R V e using GISAID sequences across January 10, 2022 12/48 different countries which are then aggregated to produce a summary estimate for each variant [24] . In general, this value is thus confounded with acquired advantage due to immunity escape, although the departure appears small within the time frame of the study (until June 3, 2021) . The values are consistent with estimates of λ V assuming substantial immune escape [25, 26] and are on the lower boundary generally accepted for the transmissibility advantage of Delta [27] .

We assume that the basic reproduction number of the original strain, R W T 0 , is approximately 3.5. There is a wide range of estimates of R W T

, ranging from about 2 to 6.5 [28, 29] . As R W T 0 depends on interaction networks in a society and will therefore plausibly differ between countries and regions, we use an estimate of R W T 0 from the early Austrian case data [30, p.13] , corrected for the assumed seasonality of 40%. concerning infections (with RT-qPCR's C t < 30) by the Alpha and Delta variants.

While [31] assesses subjects PCR-tested in weekly intervals, it is limited to people younger than 65 years old. We thus extend the lower bound of effectiveness following [32] , which also gives estimates for effectiveness of both mRNA vaccines against (symptomatic) infections with Gamma/Beta variants (in Ontario, Canada). We also use estimates from Brazil [33] for the reduction of transmission of the Gamma variant following full vaccination with vector vaccines, and from Qatar [34] and South

Africa [35] for the Beta variant. For computational simplicity, we use the resistances after a full vaccination (typically, two doses), and assign this 2 weeks after the first dose of a vector vaccine or 3 weeks for an mRNA vaccine. This is because the error arising from assigning full immunity 1-2 weeks after second dose would be larger than neglecting slightly lower immunity between doses [31, [36] [37] [38] . We assume the percentage of people who do not follow up with the second dose (when required) is sufficiently low that it can be ignored.

The reduction of probability of reinfection is based on the estimates by [31] for the WT, Alpha, and Delta variants. We assume that the probability of reinfection is reduced by 87% (84 − 90%) upon prior infection with the same variant, and it is reduced less (by 77%, (66 − 85%)) for the Delta variant when the previous infection was by a different January 10, 2022 13/48 variant (typically WT or Alpha). There is less reliable information on the reduction of re-infection for the Beta and Gamma variants. We use the model-based estimate by [26] of 70% cross-immunity (55-80%) for the Gamma variant. Based on the relative sensitivity of the variants to convalescent sera [39, 40] -and in the absence of a direct estimate of reinfection protection for the Beta variant based on a random cross-infection survey -we employ the 70% cross-immunity for the Beta variant as well. The resistances are set to approximately 75% for cross-immunity between (typically rare) combinations where we do not have direct data, and to approximately 85% for reduction in reinfection by the same strain. See Table 1 for exact values. The last two columns show resistances after immunity has waned, which we discuss in the next subsection.

The waning of immunity from both vaccines and infections plays an increasingly important role in the evolution of the COVID-19 pandemic [41, 42] . Our compartment model can be generalized to this setting. We merely need a rule to determine when and how individuals experience waning as well as an additional "intervention vaccine", i.e.

booster, given to previously vaccinated individuals.

One constraint is that our simulation does not track individuals, but groups.

Therefore, there is no concept of "time since fully vaccinated" that can be used for a gradual waning of immunity. As such, waning needs to be implemented as a transition of people from a susceptible category S h to a waned category, which will in general be written as S h− . In order to account for the different characteristics of vaccine and variant waning, this is represented in two different ways in our history notation.

Infectious variants are still given capital letters, e.g. W and A; after waning, however, these are changed to lower case, w and a. This changes a group signature from h = W A to g = W a. Note that the individual was infected by A before their resistance from W infection waned. Vaccine waning is represented by a minus sign (overloading the general notation from before), e.g. h = A1 becomes g = A1−. We assume for simplicity that a waned group cannot wane a second time. Therefore our waned vaccine group A1− cannot wane to a1−; waning only occurs for the most recent event experienced. We do not consider this to be a significant oversimplification as the first waning event results in January 10, 2022 14/48 the majority of the resistance reduction experienced and the use of booster vaccines returns people to effectively un-waned groups.

The transition between groups happens at a single point in time as opposed to a gradual decrease in immunity. On average, the waiting time before waning is chosen in order to mimic a gradual, population-level decrease in immunity. All [43, 44] . For the hypothetical variant Omega, we assume both lower initial resistance after vaccination (vector: 30% (0-55%); mRNA: 60% (50-65%)) as well as stronger waning over 180 days (vector: 0% (0-0.05%); mRNA: 0.05% (0-0.1%)). We assume that the immunity post-infection declines similarly as the one after getting a vector vaccine (see Table 1 ).

The booster shot is implemented as a new vaccine that is only given to people who have been vaccinated, regardless of their waned status. As the real "waning event" is not uniform over the entire population and it is not known whether or not someone has truly waned when given the booster shot, this is a parsimonious representation of the effects. For simplicity, we group all booster vaccine combinations together, such that there isn't any interaction effect between the booster received and any previous infection or vaccination. As the booster is implemented as a vaccine, resistances are updated according to the same rule: the resistance after receiving the booster is given by the maximum, per variant, of current resistance and the resistance provided by the booster. For Delta and older variants, the boosted resistance starts at 96% (94-98%), and wanes only slightly over 6-months, to 85% (75-90%). For the hypothetical variant Omega, we use the tentative values for vaccine effectiveness based on resistance to symptomatic infection with the Omicron variant, and assume boosted resistance starts at 70% (60-80%) and over 6 months, wanes to 30% (20-40%) -see Table 1 ).

For a simple population consisting of a single group, we have an average resistance behaving as in Fig 2. In practice, many waned compartments that receive the booster will have identical resistances. This is because their resistances γ (h−)V are below those of the booster vaccine against all variants V, and because vaccines only raise resistances to a specified level. We do not collapse the compartments, however, so that the history of a compartment can be tracked in subsequent analyses.

Given the initial conditions, equations (8) and (9) Epidemiological data in Austria is gathered and provided by AGES (Agentur für Gesundheit und Ernährungssicherheit GmbH), the Austrian agency for health and food safety [45] . In addition to tracking the number of cases, hospitalizations, deaths, and tests, AGES tracks the genome sequencing of SARS-CoV-2 samples gathered in Austria to monitor the prevalence of variants of concern (VOC) [46] . The first confirmed case of the Alpha variant in Austria was on January 3, 2021. A VOC sentinel system was subsequently established with one PCR test lab per county submitting a random sample of SARS-CoV-2 specimens for complete genome sequencing.

VOC prevalence in Austria is published online and updated roughly every one to two weeks. who were previously infected, we must account for the detection ratio throughout the entirety of the pandemic. Based on [47] and consistent with seropositivity in Austria from mid November [48] , we assume that 12% of the Austrian population was infected by the wild-type before January 1, 2021. For 2021, we specify the detection ratio which measures the (age-averaged) probability that an infected individual is diagnosed and appears in the official case statistics. Due to increases in the availability and use of COVID-testing in Austria, we use the following estimates for the detection ratio in 2021: We use a vaccine schedule to match that of Austria throughout the simulation period, as the actual vaccination plan is considered to be a background setting of our model as opposed to an intervention by a controller. We use the 7-day median of administered first doses during each calendar week [50] variants [51] [52] [53] . The Supporting Information explores other settings in which variants have generation intervals with lower mean, such as is possible for Omicron. Table 1 discusses the parameters we use and how they differ between variants. We extend that discussion here by showing how these parameters translate into dimensions of primary concern. To simplify a visual presentation, Fig 5 only Therefore, our graphs summarize which variants are of greatest concerns to regions with different vaccination rates. R hV e,t from equation (4) does not easily allow one to compare variants because it specifies both the group that is being infected as well as depends on mitigation and seasonality. Therefore, we remove the time varying components (M t L t ) and integrate R hV e,t over the susceptible populations S h :

ρ V t is the conceptual driver of outbreaks in our model as it represents the reproduction number of a variant within a particular population by accounting for susceptibility due to immune evasion.

In order to plot ρ V t as a function of the vaccination rate r ∈ populations, respectively. Note that N ≈ N va + N uv as we ignore the comparatively small set of people that are currently infected. We then have

Observe that equation (14) is merely a convex combination between ρ V t computed on two different populations: those who are vaccinated (first term) and those who are not (second term). For example, suppose that there is no resistance conferred by previous January 10, 2022 21/48 infection and perfect resistance conferred by vaccination (γ hV = 1, ∀h ∈ H uv and γ hV = 0, ∀h ∈ H va ). In this case, equation (14) simplifies to

which is just the basic reproduction number times the proportion of unvaccinated individuals. Fig 6. The reproduction number of variants accounting for immunity within the population, before mitigation and seasonality. ρ V t , defined by equation (14), is shown as a function of the proportion of the population that is vaccinated. Omega is a hypothetical variant with a higher immune escape: its relative advantage thus increases as vaccination level does. Shaded regions correspond to 50% and 95% prediction intervals resulting from the uncertainty in viral parameters summarised in Fig 5. The assumed composition of the population is depicted in Fig 4; it reflects Austria on August 8, 2020, with about 20% of population recovered from infections, mainly by WT (75%), Alpha (22%) and Delta (3%). For simplicity, we assume that vaccination is independent of the infection history. Different population compositions and immunity waning are addressed later (Figs 7 and 16 ). with Delta being considerably riskier than Omega. When vaccination rates are higher than approximately 70%, however, the ordering switches and Omega becomes the Table 1 . Shaded regions correspond to 50% and 95% prediction intervals resulting from the uncertainty in viral parameters summarised in Fig 5. riskiest -with the highest ρ V t .

ρ V is the conceptual driver of outbreaks in our model as it represents the reproduction number of a variant within a particular population, accounting for its susceptibility due to immune evasion. Furthermore, herd immunity is understood in context of current mitigation. This means that populations with greater acquired immunity (lower ρ V ) can use fewer NPIs to receive the benefit of dissipating epidemics.

Populations with higher ρ V will need either need higher NPIs in order to suppress an outbreak, or require very strict border controls to prevent importing and allowing community spread of a high-risk variant.

One long-standing question has been how best to control COVID-19 outbreaks when they arise. This subsection explores which statistics should be considered when January 10, 2022 24/48 determining whether to increase or decrease mitigation measures, particularly after the introduction of a new SARS-CoV-2 variant with higher effective reproduction number.

Two controller types are considered that either respond to increases in case numbers ("reactive" control) or to increases in an estimate of the reproduction number ("proactive" control). We find that using an estimate of the effective reproduction number in addition to case numbers is a much more efficient strategy.

Responding to the effective reproduction number further helps to address a potential endogeneity effect due to increasing prevalence of COVID-19, i.e., individuals may modify their behavior when the situation either worsens or improves. Most public reporting discusses solely case numbers, so it may be reasonable to assume that individuals base decisions more on either absolute case levels or strong increases in cases.

This can be problematic at the start of a wave if case numbers are incredibly low: purely measuring absolute increases or case-number thresholds may trigger a response too slowly. On the other hand, as the reproduction number is not given the same attention in the media, individuals may not change behavior dramatically when it changes. This helps connect NPIs to simulation dynamics, as individuals are not also responding to the same statistics as our NPIs.

As mentioned above, we consider two specific control settings. The first, termed "reactive", only responds to case numbers. There is an upper bound, above which stricter NPIs are used, and a lower bound, below which NPIs are relaxed. This is crafted to mimic the EU protocols for measuring the riskiness of non-essential travel, which assign color codes to regions depending on their publicly reported epidemiological data such as 14-day rate of cases, deaths, and/or tests administered [4] . Being below the lower boundary corresponds to being "green" whereas above the upper corresponds to being "red". In our results, we show a reactive controller with two different sets of thresholds.

The first set, referred to as "low-positivity", uses a lower bound of 25 cases per 100,000

and an upper bound of 150 cases per 100,000 (both measured over a 14-day period).

This corresponds the recommendations for a low test-positivity region. The second set, referred to as "high-positivity", uses also a lower bound of 25 cases per 100,000 but an upper bound of 50 cases per 100,000 (both measured over a 14-day period). This is far stricter and corresponds to recommendations for a high test-positivity region.

The second control, termed "proactive", responds to both case numbers and the January 10, 2022 25/48 effective reproduction numberR e,t in equation (12) . We start the simulation on June 12, 2021, as that corresponds to the AGES estimates for Delta prevalence in Austria (see Fig S7 in the Supporting Information).

The same initialization process was used as discussed previously, merely until June 12 instead of August 8. All other parameters needed to initialize our simulations are also taken from observed data on this day. This includes history of new cases, the proportion of population that is vaccinated or previously infected, etc. Simulation results for the low-positivity thresholds are shown in Fig 9, which shows daily incidences (case numbers), the effective mitigation levelM t (reduction inR e,t due to NPIs), and the current estimate of the effective reproduction numberR e,t . These additional graphs can be used to more precisely monitor both the simulated COVID-19 [3, 4] ); note that the thresholds, 25 resp. 150 per 100,000 within 14 days, are divided by 14 as the y-axis shows daily incidence. The shaded regions gives the 50% (dark) resp. 95% (light) prediction interval. The 7-day moving average of the actual incidence in Austria is given by the height of the gray, shaded area, and data past October is not shown as cases were allowed to dramatically increase under relaxed NPIs. The simulation under reactive control accurately predicts new cases three months after initialization.

intact. Proactive control not only reduces the median infections and peak quarantine cases, but does so much more reliably: the observations cluster much more strongly around the median. As seen in Fig 10, reactive control has not only higher median values, but also a much more skewed distribution: it is possible to experience massive spikes before the outbreak is brought under control. Given the skewness of the distributions for the reactive controller, difference in medians is measured via a Proactive control reduces total infections as well as peak numbers in quarantine. With proactive control, the extent on NPIs reflects not only the active cases but also the estimated reproduction numberR e,t (see section Controllers). The difference in medians and corresponding 95% confidence intervals for total infections per 100,000 (over the simulated period) and peak quarantined cases per 100, 000 are, respectively, 509.6 (450, 580) and 108.2 (99, 118).

Comparing the distributions of the strengths of NPIs used by the two controllers provides a more rigorous understanding. Fig 11 shows the density of the difference between the observed mitigation and the "balanced" mitigation level,M * t , defined to be that value for which the effective reproduction numberR e,t = 1 in equation (12) . Note thatM * t changes over time due to changes in variant prevalences, seasonality, and acquired immunity in the population. As a reminder, lower values ofM t correspond to stronger NPIs. We see that proactive control trades more time with moderate mitigation for less time at extreme mitigation.

Next, we examine the robustness of these conclusions by using stricter case number thresholds for the controllers as recommended for a higher positivity rate. Fig 12 shows that with stricter case thresholds, simulated cases are much lower because NPIs are triggered more quickly for both controllers. Yet, under a reactive controller, case numbers and the effective reproduction number exhibit a "yoyo" effect, in which they relatively rapidly cycle through periods of increase and decrease. This effect can also be seen for the low-positivity thresholds of Fig 9, but the timescale is much longer. In general, large peaks lead to sufficiently strict NPIs that subsequent peaks appear much Proactive control uses mitigation close to the "balanced" level. We define the "balanced" mitigation level,M * , to be that value for which the effective reproduction numberR e,t = 1. Note that lower values ofM t correspond to stronger NPIs. We can see that with higher case thresholds (a), the proactive controller spends more time around this value as well as avoids extreme deviations. With lower case thresholds (b), the proactive controller fares even better, as holding mitigationM t slightly belowM * is sufficient to alleviate the epidemic without unnecessarily strict NPIs.

later in our simulations. The proactive controller is much more efficient and eliminates this behavior almost entirely. In particular, the left column of Fig 9 shows on average less strict NPIs than Fig 12. The box plots of total infections and peak quarantined cases (see Supporting

Information, Fig S1) show that with stricter thresholds, median values are closer together. Reactive control fails to provide reliable control, however, in that some simulated trajectories still produce many infections and quarantined cases. The difference in median total infections per 100,000 is 53.2 (95% CI: 29, 79) and the difference in median peak quarantined cases is 16.8 (95% CI: 14, 20) . That being said, the 97.5% quantile of peak quarantined cases of the reactive controller is twice as high as that of the the proactive one. The mitigation graph for this setting is shown in Fig   11 . Proactive control continues to use a more measured response, whereas reactive control prefers more extreme mitigation levels. In fact, the proactive controller primarily holdsM t slightly belowM * t , which is sufficient to alleviate the epidemic without unnecessarily strict NPIs.

From the point of view of feasibility, the proactive controller makes far fewer Fig 12. The proactive control is more efficient than reactive control even when incidence thresholds are stricter. Stricter thresholds are used such that NPIs are increased when the incidence is 50 per 100,000 inhabitants over a 14 day period. This creates a "yoyo" effect under reactive control that is effectively prevented with proactive control. All other parameters are as in Fig 9. interventions than the reactive controller. While a strict reactive controller does keep case numbers low, this results in interventions which occur almost every two weeks.

This is the minimum period that we specify in our model as a gap between interventions.

It is unlikely that a government would be able to so regularly change policy.

This section introduces a new hypothetical SARS-CoV-2 variant that occupies both a reasonable and empty region of the infectiousness graph in Fig 6. The hypothetical variant, termed Omega, has a lower basic reproduction number than Delta but evades immunity after vaccination or infection by older variants more easily. This provides a scenario in which even a relatively highly vaccinated community will still experience an outbreak and the possibility to explore policies used during the winter of 2021 and January 10, 2022 31/48 spring 2022. Omega is introduced as a weekly import, and for simplicity, one case is imported per day. The distribution of imported infections has no effect on the results, regardless if infections are imported daily or staggered throughout the week. All other parameter and control settings are the same as in the previous subsection on Delta.

While this paper was under revision, variant Omicron has emerged and spread. As it is conceptually similar to our Omega variant, we updated the resistance parameters for

Omega to mirror tentative estimates of these parameters for Omicron. Yet the lack of concrete values for other parameters such as mean generation interval and waning of vaccine effectiveness against infection prevent us from making concrete claims about

Omicron. As such, we have maintained the name Omega in order to emphasize the inability to properly mimic Omicron at this point in time. The largest difference between scenarios with and without Omega is the width of the infection prediction intervals for the reactive control. Not only does the reactive control allow larger outbreaks, but it is unable to guarantee that all simulation paths are controlled. In approximately 2.5% of simulations, infections peaked at 40 cases/100,000.

The proactive control was able to provide more efficient and reliable control on all simulation instances, effectively preventing an outbreak. This can also be seen by its ability to keep the effective reproduction number stable and near 1. The difference in median total infections per 100,000 is 297.1 (95% CI: 236, 361) and the difference in median peak quarantined cases is 20.9 (95% CI: 13, 29) . The difference in the 97.5%

quantiles of predicted infections is over 2,000 cases/100,000, while for predicted peak cases in quarantine the difference is over 400 cases/100,000 (see Fig S2) .

As vaccinations increase, some governments may react to hospitalised (or ICU-hospitalised) incidence instead of case numbers. The rationale is that the controller Fig 13. The reactive control fails to contain new variants that are competitive in highly-vaccinated populations. The figure shows a scenario with a hypothetical variant Omega that has a smaller basic reproduction number than Delta but has a greater ability to escape immunity post vaccination or infection by other variants (cf. Fig 6) . Proactive control prevents an outbreak and uses fewer NPIs overall.

Other parameters are the same as in Fig 12; note the longer gaps between peaks, which are the result of larger preceding peaks and extended time under more NPIs.

decides based on hospital capacity, rather than managing the cases. This is particularly enticing as the vaccines reduce severe illnesses or hospitalizations even more than mere

infections. Yet this results in a larger delay between infections and actionable information, as there is a larger delay between infection and hospitalization. While we do not model hospitalizations as this would require adding an age structure to all of our compartments, we can increase the delay that the controller uses for observing cases.

This isolates the effect of the delayed information. If hospitalizations are a constant multiple of infections, then our results translate directly to that domain as well. but the case data informing this decision is 21 days old. This corresponds to the approximate 2-3 week delay between infection and hospitalization at ICU [54] . We see that the initial outbreaks are significantly more pronounced (cf. Fig 13) : both controllers begin the simulation by merely increasing mitigation as rapidly as possible.

The subsequent outbreak, however, is entirely prevented by the proactive controller, even with delayed information. In fact, the proactive controller using a 21 day delay prevents outbreaks significantly better than a reactive controller with only 7 day delay (cf. Fig S2 and Fig S3) .

Controller with a larger delay leads to significantly more pronounced outbreaks, especially with reactive control. The figure shows a controller with a 3-week delay. A similar delay would be expected when decisions are based on hospitalizations due to COVID-19 rather than on cases. We (conservatively) assume the case thresholds would stay the same. Compare with Fig 13, where the controllers respond with a 1-week delay.

One additional effect of delayed information is that restrictions are not lifted in a timely manner. Both controllers maintain the restrictions longer than necessary. This gives rise to the more diffuse mitigation density used by the proactive control as seen in into the spring. In reality, we expect a government to relax sooner, but at the cost of future waves also arriving sooner. In both settings, proactive control uses mitigation much closer to the balanced value, while the reactive controller compensates for overly lax NPIs by using overly strict NPIs. The degradation in information by using a larger delay is clearly seen in the additional dispersion of the proactive mitigation density. The modal value, however, still achieves balance between strict NPIs and preventing outbreaks.

Comparing the difference in peak quarantined cases carries additional meaning in this setting as it is highly correlated with peak hospitalizations. While the medians are again similar, the maximum peak quarantined cases over simulations are nearly twice as high for the reactive controller as for the proactive controller ( Fig S3) . Proactive control suffers much less from looking at more delayed data than reactive control. As such, this

indicates that looking at rates of change in hospital can be a good indicator, while the delay from reacting to actual hospital utilization is costly.

In the simulation results presented above, populations always increase their immunity to new infections over time, either through vaccination or through infections. In reality, the induced immunity also wanes over time. We focus on simulations with the Omega variant, as it is assumed to be most susceptible to waning. With waning immunity and boosting, the variant risk as measured by ρ V changes non-monotonically over time (see Fig 16) . While boosting rapidly increased in October and November, its strongest effect January 10, 2022 35/48

on ρ V appears delayed. This is because all vaccinated individuals are eligible for the booster, not just those with waned immunity. The sheer size of the vaccinated groups means many doses need to be administered before the waned groups dramatically decrease in size. The effects of this changing risk profile can also be seen in the infection outbreaks that occur in the simulations and the subsequent controller behavior. graph with boosting is in the Supporting Information (Fig S4) , as adding boosting is sufficient to suppress the Omega outbreak in the winter. For simplicity, we focus only on the strict case thresholds of 25 and 50/100,000/14 days. In the summer, the relative advantage of Omega is too low to see an outbreak in the presence of relatively strong mitigation. Waning immunity then leads to a larger outbreak of the Omega variant than observed without waning in Fig 13, though only under reactive control. The winter outbreak is even suppressed when the proactive controller uses looser, 25-150/100,000/14 days case thresholds (Fig S5) .

In terms of comparison of the controllers, the results of the previous section (without waning and boosting) still hold. There are significant differences in the medians for both total infections and peak quarantined cases between reactive and proactive control. The differences in the upper quantiles of these predicted distributions is even more extreme.

We can see in Fig 18 that for both low and high thresholds, the reactive controller tends to use extremely high or low mitigation levels, consistently failing to find a balance between suppressing outbreaks and NPI use. In fact, switching to stricter case thresholds exacerbates this problem.

Lastly, we briefly explored simulation dynamics when Omega is modified to spread even more rapidly. In addition to the high immune escape of our baseline Omega variant, we increased its base reproduction number to 2-matching Delta-and reduced the mean of the generation interval from 4.6 days to 3 days (CI: 1.5, 4.5). Such a variant has a significant potential to cause extremely large outbreaks if not controlled efficiently.

We confirmed that while the proactive controller suppresses the potential outbreak, the reactive controller does not, even with strict case control thresholds (see Fig S6) .

The model and simulation that we develop provides significant insight into efficient control strategies of COVID-19 outbreaks. The key behavior which we wanted to Fig 18. With waning, which accelerates and strengthens the Omega outbreak, reactive control fails to balance NPI use. For both high (a) and low (b) control case thresholds, proactive controller is more efficient. The rising ρ V values in simulations with waning apply the greatest pressure toward an epidemic outbreak, which the proactive controller contains efficiently, without resorting to extreme NPIs. capture in our simulation was a complex interaction between diverse groups in a compartment model. Our simulation creates compartments for various vaccines, multiple SARS-CoV-2 variants, and specifies well-supported parameters for them all.

The interaction rules between compartments are transparent. This allows us to simulate complex scenarios in a realistic and dynamic setting: COVID-19 epidemic spread in Austria. Having such a realistic model is an integral component to controlling outbreaks, as having a good model a system is a prerequisite for regulating it efficiently [55] .

It is well known that timely restrictions are more efficient in controlling an epidemic [56, 57] ; yet timely decisions can only be taken with a good controller. One can consider addressing this in two distinct ways: 1, use stricter thresholds of a given statistic to motivate change; or 2, use a better statistic, preferably informed by a model of the epidemic [55] . Our study demonstrates that the second type of solution, using the effective reproduction number R e,t to guide intervention decisions in addition to case numbers, is more efficient and successful at curbing the epidemic. We provide a quantitative comparison of a continuous controller of two types -one which only reacts to cases (reactive), and one which also reacts to the effective reproduction number (proactive). We show that the proactive controller is more efficient and effective at controlling infection outbreaks than the reactive controller, even when it uses data that January 10, 2022 38/48 has a larger delay (such as using R e,t estimated from hospitalizations). In contrast, the NPIs imposed by the reactive controller are further away from the more efficient "balanced" minimum intervention policy which keeps R e,t close to 1. By oscillating between over-and under-regulating, the reactive controller fails to provide reliable control of new outbreaks: some simulation paths exhibit large spikes in infections and peak quarantined cases, even when the median values are controlled.

A potential limitation of our simulation is our lack of observation level model which would allow us to simulate a fluctuating detection ratio. While some view positivity-rate to be informative about the detection ratio, we -in the absence of a well-informed model for testing strategies and its saturation -instead consider a range of case-based thresholds which span the gamut of positivity rate scenarios. In all of these settings, we find consistent support for using a proactive control strategy that responds to changes in the effective reproduction number.

Our model does not explicitly incorporate any network structure for individuals'

interactions; each individual in the simulation interacts independently with all other members. In reality, infections take place in the household, work, and social environments. The different cross-contamination rates in these environments lead to clusters of observed infections, not only in terms of infections occurring, but also in terms of identifying them via contact tracing. This is partially alleviated by our model accounting for super-spreading. Large super-spreading events are often caused by high infectiousness coupled with a particular network structure. By incorporating super-spreading natively in our model, we are able to produce cluster-like effects due to people that are significantly more contagious than others. Furthermore, other changes in network structure are captured by seasonality or mitigation; seasonality can be caused by increased indoor interaction during winter months, and social distancing rules are common NPIs.

Our model contains many parameters governing diverse characteristics such as vaccine effectiveness, resistance to reinfection (including cross-infection by other variants), and basic reproduction numbers. A natural question is which of these has a stronger effect on the simulation. The difficulty in answering lies in the distribution of the population across the compartments we describe. Populations with lower vaccination rates but higher rates of previous infection will naturally be more sensitive January 10, 2022 39/48

to cross-infection rates and vice versa. That is why we defined the ρ V parameter, which characterizes a decisive component of the effective reproduction number. It depends on the basic reproduction number as well as the reduction in transmissibility arising from the (partial) immunity acquired by previous infections and vaccinations within a particular population. We believe ρ V is an important summary parameter of great relevance.

The paper is not intended to forecast what the future of SARS-CoV-2 will bring:

potentially vaccine resistant variants, or variants with even higher base reproduction number, etc. The next important VOC may well have different characteristics to the hypothesised Omega. It is important to keep in mind though, that same VOCs which appear to be currently out-competed by (say) Delta may have a competitive advantage later. The possibility of change in the relative advantage between variants is especially relevant when the emerging variant leads to more severe symptoms. The main claims of this paper, however, hold true for all of these possibilities. Regardless of the process leading to future waves, one certainty is that they will occur. In this eventuality, governments must design methods to identify and react to changes in the pandemic.

Our results focus on this common denominator. [31, 32] 0.94 [31, 32] 0.75 [34] 0.85 [32] 0.84 [31, 32] 0.6 [44] 0.5 [43, 44] 0.05 [44] 0.86 [31] 0.86 [31] 0.1 [35] 0.65 [33] 0.7 [31] 0.3 [44] 0.4 [43, 44] 0 [44] 0.96 [44] 0.96 [44] 0.96 [44] 0.96 [44] 0.96 [44] 0.7 [44] 0.85 [44] 0.3 [44] [31] 0.87 [31] 0.7 [26] 0.7 [39, 40] 0.77 [31] [31] 0.87 [31] 0.7 [26] 0.7 [39, 40] 0.77 [31] [26] 0.7 [39, 40] 

Inferring the effectiveness of government interventions against COVID-19

Understanding the effectiveness of government interventions in Europe's second

World Health Organization. Critical preparedness, readiness and response actions for COVID-19: interim guidance

Draft Council Recommendation on a coordinated approach to the restriction of free movement in response to the COVID-19 pandemic

Optimal COVID-19 containment strategies: Evidence across multiple mathematical models

Harnessing multiple models for outbreak management

Disease momentum: Estimating the reproduction number in the presence of superspreading

A new framework and software to estimate time-varying reproduction numbers during epidemics

Schätzung des seriellen Intervalles von COVID19

Estimating effective reproduction number using generation time versus serial interval, with application to covid-19 in the Greater Toronto Area

Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data

Generation time of the Alpha and Delta SARS-CoV-2 variants

Serial interval and basic reproduction number of SARS-CoV-2 Omicron variant in South Korea

Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China

Coronavirus occurrence and transmission over 8 years in the HIVE cohort of households in Michigan. The Journal of infectious diseases

Seasonality of respiratory viral infections. Annual review of virology

Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1

Seasonal stability of SARS-CoV-2 in biological fluids

Drivers of infectious disease seasonality: potential implications for COVID-19

Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period

Seasonal variation in SARS-CoV-2 transmission in temperate climates

Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study

Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers

Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at

Co-circulation of SARS-CoV-2 variants B.1.1.7 and P.1. medRxiv

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus

Infections and Spread

The reproductive number of COVID-19 is higher compared to SARS coronavirus

A systematic review of COVID-19 epidemiology based on current evidence

A COVID-19 compartment model for Austria

Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. medRxiv

Effectiveness of COVID-19 vaccines against variants of concern in Ontario

Effectiveness of the ChAdOx1 vaccine in the elderly during SARS-CoV-2 Gamma variant transmission in Brazil

Effectiveness of the BNT162b2

Covid-19 vaccine against the B.1.1.7 and B.1.351 variants

Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum

Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

SARS-CoV-2 vaccine protection and deaths among US veterans during 2021

SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 33

AGES Dashboard COVID19

SARS-CoV-2-Varianten inÖsterreich

Evaluation of undetected cases during the COVID-19 epidemic in Austria

Press-conference 12.396-236/20

Model Based Estimation of the SARS-CoV-2 Immunization Level in Austria and Consequences for

COVID-19 vaccination data for Austria

Spread of the Delta variant, vaccine effectiveness against PCR-detected infections and within-host viral load dynamics in the community in France

Serial intervals in SARS-CoV-2 B.1.617.2 variant cases. The Lancet

Inference of SARS-CoV-2 generation times using UK household data. medRxiv

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet

Every good regulator of a system must be a model of that system

Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study. The Lancet Infectious Diseases

Key epidemiological drivers and impact of interventions in the 2020

SARS-CoV-2 epidemic in England

We would like to thank Astrid Christine Erber, Joachim Hermisson, Michal Hledík , Pavel Payne and Claudia Zimmermann for insightful discussions and comments on earlier drafts.